Selenium supplementation acting through the induction of thioredoxin reductase and glutathione peroxidase protects the human endothelial cell line EAhy926 from damage by lipid hydroperoxides by Lewin, Michelle H et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Selenium supplementation acting through the induction of
thioredoxin reductase and glutathione peroxidase protects the
human endothelial cell line EAhy926 from damage by lipid
hydroperoxides
Citation for published version:
Lewin, MH, Arthur, JR, Riemersma, RA, Nicol, F, Walker, SW, Millar, EM, Howie, AF & Beckett, GJ 2002,
'Selenium supplementation acting through the induction of thioredoxin reductase and glutathione peroxidase
protects the human endothelial cell line EAhy926 from damage by lipid hydroperoxides' Biochimica et
Biophysica Acta (BBA) - Biomembranes, vol 1593, no. 1, pp. 85-92. DOI: 10.1016/S0167-4889(02)00333-6
Digital Object Identifier (DOI):
10.1016/S0167-4889(02)00333-6
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Biochimica et Biophysica Acta (BBA) - Biomembranes
Publisher Rights Statement:
elsevier's open access
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 28. Apr. 2017
Selenium supplementation acting through the induction of thioredoxin
reductase and glutathione peroxidase protects the human endothelial cell
line EAhy926 from damage by lipid hydroperoxides
Michelle H. Lewina, John R. Arthurb, Rudolph A. Riemersmac,d, Fergus Nicolb,
Simon W. Walkera, E. Margaret Millard, Alexander F. Howiea, Geoffrey J. Becketta,*
aUniversity Department of Clinical Biochemistry, The Royal Infirmary, Lauriston Place, Edinburgh EH3 9YW, UK
bRowett Research Institute, Bucksburn, Aberdeen AB21 9SB, UK
cMedical Physiology, University of Tromsø, Norway
dCardiovascular Research Unit, University of Edinburgh, Hugh Robson Building, George Square, Edinburgh EH8 9XD, UK
Received 28 May 2002; received in revised form 20 September 2002; accepted 25 September 2002
Abstract
The human endothelial cell line EAhy926 was used to determine the importance of selenium in preventing oxidative damage induced by
tert-butyl hydroperoxide (tert-BuOOH) or oxidised low density lipoprotein (LDLox). In cells grown in a low selenium medium, tert-BuOOH
and LDLox killed cells in a dose-dependent manner. At 555 mg/l LDLox or 300 AM tert-BuOOH, >80% of cells were killed after 20 h. No
significant cell kill was achieved by these agents if cells were pre-incubated for 48 h with 40 nM sodium selenite, a concentration that
maximally induced the activities of cytoplasmic glutathione peroxidase (cyGPX; 5.1-fold), phospholipid hydroperoxide glutathione
peroxidase (PHGPX;1.9-fold) and thioredoxin reductase (TR; 3.1-fold). Selenium-deficient cells pre-treated with 1 AM gold thioglucose
(GTG) (a concentration that inhibited 25% of TR activity but had no inhibitory effect on cyGPX or PHGPX activity) were significantly
(P < 0.05) more susceptible to tert-BuOOH toxicity (LC50 110 AM) than selenium-deficient cells (LC50 175 AM). This was also the case for
LDLox. In contrast, cells pre-treated with 40 nM selenite prior to exposure to GTG were significantly more resistant to damage from tert-
BuOOH and LDLox than Se-deficient cells. Treatment with GTG or selenite had no significant effect on intracellular total glutathione
concentrations. These results suggest that selenium supplementation, acting through induction of TR and GPX, has the potential to protect the
human endothelium from oxidative damage.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Endothelial cells are continually exposed to a pro-oxidant
environment in the vasculature, and to the possibility of
damage by reactive oxygen species, hydrogen peroxide and
lipid peroxides, etc. [1–3]. Oxidised low density lipoprotein
(LDLox) is an important mediator of oxidative damage to the
endothelium [4–6], and is directly cytotoxic to human
endothelial and smooth muscle cells [7–11]. Lipid perox-
idation of LDL bymetal ions or by cells in vitro gives rise to a
large variety of primary and secondary products from the
lipid constituents. Some of these products react with the
lysine groups of apoprotein B, resulting in recognition by
the scavenger receptor [7]. Other products are cytotoxic [11].
Oxidative damage to the endothelium by LDLox may be
one of the principal mechanisms in the pathogenesis of
atherosclerosis [1–3]. Protection against oxidative damage
is achieved through numerous enzymatic and non-enzy-
matic systems [12,13]. It has been suggested that the
development and progression of atherosclerosis may be
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inhibited by selenium (Se). This essential trace metal exerts
antioxidant actions through increased expression of sele-
noenzymes, such as the family of glutathione peroxidases
(GPX) [14–17]. More recent evidence has suggested that
the selenoenzyme thioredoxin reductase (TR; EC 1.6.4.5)
may be particularly important in providing an antioxidant
role in the human endothelium [17,18].
Studies using cultured animal endothelial cells have
provided convincing evidence that Se is essential to provide
maximum protection from oxidative damage. For example,
bovine aortic endothelial cells (BAEC) in culture are more
resistant to cytotoxic damage by photo-generated LDLox or
tert-butyl hydroperoxide (tert-BuOOH), when pre-treated
with sodium selenite compared with unsupplemented con-
trols [16]. This resistance was ascribed to increased expres-
sion of cytoplasmic GPX (cyGPX; EC 1.11.1.9) and phos-
pholipid hydroperoxide GPX (PHGPX; EC 1.11.1.12). The
involvement of other selenoenzymes, such as TR, in such a
protective role was not considered.
TR is a homodimeric selenoenzyme belonging to the
flavoprotein family of pyridine nucleotide-disulfide oxidor-
eductases, which include lipoamide dehydrogenase and
glutathione reductase [19]. Each subunit of TR has a
selenocysteine residue as the penultimate amino acid residue
at the carboxyl terminal that is essential for catalytic activity
of the enzyme [19]. Three isoforms of TR have been
identified in humans, one mitochondrial and two cytoplas-
mic. They share considerable homology (reviewed in Ref.
[20]). The predominant isoform of TR is the ubiquitous
cytoplasmic form, TR1 [20]. TR is a multifunctional sele-
noprotein that, in conjunction with thioredoxin (Trx) and
NADPH, forms a powerful dithiol-disulfide oxidoreductase
system. TR1 can reduce and detoxify lipid hydroperoxides,
hydrogen peroxide, and organic hydroperoxides directly
using NADPH as a cofactor [19–21]. In addition, TR1
restores bioactivity in some enzymes inactivated by oxida-
tive stress [22]. It can regenerate ascorbic acid from dehyr-
oascorbate [23]. The TRs may also exert antioxidant action
through their ability to reduce thioredoxin [19,20].
The GPXs have antioxidant function in the cell [24], with
cyGPX catalysing the reduction of hydrogen peroxide and a
variety of hydroperoxides [25]. PHGPX is capable of
catalysing the reduction of phospholipid hydroperoxides
and cholesterol hydroperoxides, many of which are not
substrates for cyGPX [26]. TR can detoxify hydrogen
peroxide and lipid peroxides more efficiently than the GPXs
under certain conditions [21]. This, together with the high
expression of TR in human EC [17,18], suggests that the
selenoenzyme may be more efficient than the GPXs in
defence against oxidative damage. Thus, it is possible that
decreased expression and activity of these selenoproteins as
a result of Se deficiency in man, increases the susceptibility
of the endothelium to oxidative damage by LDLox or other
lipid hydroperoxides.
Gold thioglucose (GTG) interacts with Se residues in
selenoenzymes [27], and thus inhibits their activity. Sele-
noenzymes show marked variation in their sensitivity to
inhibition by GTG. The GPXs are relatively resistant to
inhibition by gold compounds. TR is very sensitive, having
an IC50f 1000-fold lower than that of the GPXs [28]. Gold
compounds can be administered to animals in specific doses
that can inhibit TR activity without modifying the activity of
the GPX [29]. Thus, the use of different concentrations of
GTG may offer a convenient tool to elucidate the relative
importance of selenoenzymes in antioxidant defence of
endothelial cells.
Sodium selenite pre-treatment affords protection against
the harmful effects of tert-BuOOH in human endothelial
cells from different sources [17]. However, no studies in
human endothelial cells have investigated the possibility
that Se can protect such cells from the harmful effects of
LDLox. The human endothelial cell line EAhy926, estab-
lished by hybridising primary human umbilical vein endo-
thelial cells (HUVEC) with A549 human lung tumour cells
[30], has been used in a number of functional studies.
EAhy926 retain many of the differentiated functions com-
mon to primary endothelial cells beyond 100 passages.
These functions include the expression of von Willebrand
Factor [30], prostacyclin formation [31], and expression of
endothelin-1 [32]. This cell line is susceptible to damage
from LDLox [10]. We have used this as a model system to
determine if human endothelial cells can be protected from
the harmful effects of LDLox by selenite. In addition, we
have used GTG at selective concentrations that predomi-
nantly inhibit TR, to examine whether the enzyme plays a
significant antioxidant role in human endothelial cells.
2. Materials and methods
2.1. Chemicals and cell culture reagents
GTG, sodium selenite, 5,5V-dithiobis(2-nitrobenzoate)
(DTNB), hydrogen peroxide, hypoxanthine, glutathione,
aminopterin, thymidine media supplement (HAT), lactate
dehydrogenase (LDH) assay kit, NADPH, and tert-BuOOH
were supplied by Sigma Aldrich, Poole, Dorset, UK.
Dulbecco’s modified Eagle’s medium (DMEM) with (25
mM HEPES) and 4500 mg/l glucose, phosphate-buffered
saline (PBS), Earle’s balanced salt solution (EBSS), foetal
bovine serum (FBS) were supplied by Gibco, Life Tech-
nologies, Paisley, UK.
Cell culture plastics were supplied by Iwaki, Japan.
2.2. Cell culture
The human endothelial cell line EAhy926, derived from
umbilical vein endothelial cells, was a kind donation from
Professor C.-J.S. Edgell, University of North Carolina,
Chapel Hill, NC, USA. The cell line was maintained in
high glucose (4.5 g/l) DMEM containing 10% FBS, 5 mM
hypoxanthine, 0.02 mM aminopterin, and 0.8 mM thymi-
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dine, in a humidified atmosphere of 5% CO2, 95% air at 37
jC. The cells were passaged weekly using 0.25% trypsin–
0.02% EDTA solution. EAhy926 cells displayed the char-
acteristic morphology of endothelial cells in culture and
stained positively for von Willebrand Factor.
The selenium content of the basal medium (without
FBS), determined by acid digestion followed by fluorimetric
analysis [33,34], was 0.35 nM and was classified as ‘sele-
nium-deficient medium’.
2.3. Determination of cellular integrity by measurement of
LDH retention
Cell viability was assessed, in 24-well plates, as the
percentage retention of LDH by the cell layer after 20 h
exposure to tert-BuOOH or LDLox. Intracellular LDH activ-
ity in cells and in the culture medium was determined using a
kit method (Sigma Diagnostics), modified for use on the
Cobas Fara centrifugal analyser (Roche Diagnostics,Welwyn
Garden City, UK). The culture medium (1 ml) was removed
for analysis, and the cells washed twice with 1 ml EBSS. The
cells were then lysed in 0.5 ml of 0.5% Triton X-100 (in PBS,
pH 7.4). After 15 min, the cell lysates were collected and the
wells were washed with a further 0.5 ml EBSS and the
washings combined with the respective lysates. Cell debris
in the culture medium and cell lysates was removed by
centrifugation at 11,500 g for 10 min prior to assay.
The LDH activity was also measured in culture media
that had not been in contact with cells as a measure of
endogenous LDH in the culture medium (blank). All results
were blank-corrected. Results were expressed as percent
LDH activity retained.
2.4. Total protein measurement
The Bradford assay [35] was used to measure total
protein in the native LDL, oxLDL and cells using BSA as
the standard. All enzyme activity results were corrected for
total protein measured using this method.
2.5. Measurement of TR activity
TR activity was measured by an optimised method based
on the method of Hill et al. [36] using DTNB (5 mM) as
substrate in the presence and absence of 720 nM GTG (final
concentration). This method was adapted for use on the
Cobas FARA centrifugal analyser (Roche Diagnostics). All
samples were measured in duplicate. Results were corrected
for total protein content and one unit of TR activity was
defined as 1 Amol of DTNB reduced per minute.
2.6. Measurement of cytoplasmic GPX, phospholipid GPX
and total glutathione
cyGPX activity was measured by monitoring the rate of
oxidation of NADPH at 340 nm in the presence of H2O2
(2.2 mM), using a Unicam UV/Vis spectrometer (UV4)
linked to a computer installed with ‘Vision’ software [37].
All samples were measured in triplicate and results were
corrected for total protein concentration. PHGPX activity
was determined using the same assay system as for
cyGPX, but with phosphatidyl choline hydroperoxide as
the substrate. Total glutathione was measured according to
Tietz [38], and adapted for use on a Cobas FARA cen-
trifugal analyser. All samples were measured in triplicate
and results corrected for total protein [35]. One unit of
GPX activity was defined as 1 Amol of NADPH oxidised
per minute.
2.7. Preparation of LDLox
LDL was isolated from 300 to 450 ml of human citrate
plasma (Blood Transfusion Service, Edinburgh) by ultra-
centrifugation using a Ti 45 rotor in a Beckman L8.55
ultracentrifuge (Beckman, Glenrothes, UK). Plasma (45 ml)
was overlayered with 15 ml of a buffered saline solution (q
1.019 g/ml) containing EDTA (10 mg/l) and centrifuged for
18 h at 186,000 g max at 4 jC. The very low density
lipoproteins were discarded. The density of the infranatant
(40 ml) was adjusted to 1.063 g/ml by addition of 14.7 ml of
buffered saline (q 1.182 g/ml), overlayered with 5.3 ml of
saline solution (q 1.063 g/ml) and recentrifuged for 18 h at
186,000 g. The LDL fraction was removed and trans-
ferred into 30 cm dialysis tubing (7.5 mm diameter, Spectra/
Por, MW cut-off 300,000; Medicel, London) and dialysed
overnight against 5 l of PBS (pH 7.4, 0.2 g/l chelex resin).
The combined dialysates of known protein concentration
were divided, one part was kept as native LDL (control for
experiments) and the other was used to prepare LDLox as
follows. Approximately 25 ml native LDL was oxidised at
37 jC using CuCl2 (Cu–protein ratio 0.16 Amol/mg pro-
tein), and the formation of conjugated dienes monitored at
234 nm. At peak absorbance (usually 60–90 min after
initiation), 10% excess EDTA was added to stop lipid
peroxidation and the volume of the lipoprotein fraction
was reduced to f 5–10 ml using a 30,000 MW cut-off
polyethersulfone filter and an Amicon 52 filtration unit
(Amicon Millipore, Bedford, MA, USA). Traces of Cu2 +
were then removed by chromatography over a Sephadex
G25 column (PD-10; Amersham Pharmacia Bio-Technics,
Uppsala, Sweden) using PBS as the eluant. The tube
containing LDLox was flushed with a 0.22 Am filtered
stream of argon, and the LDL stored at 4 jC until required
(within 2–3 weeks). Native LDL was treated in an identical
manner (filtration, chromatography, storage under argon)
except the fraction was not exposed to Cu2 +.
2.8. Statistical analysis
Comparison of all data was performed using ANOVA
and the Student’s t-test (with Welch correction as appropri-
ate) for unpaired data. Enzyme activities in Table 1 were
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compared using ANOVA with Fisher’s test for least signifi-
cant difference.
3. Protocols
3.1. The ability of selenite to prevent tert-BuOOH and
LDLox toxicity
EAhy926 cells were passaged into 24-well plates at a
density of 5105 cells/cm2 and left to grow in high glucose
(4.5 g/l) DMEM containing 10% FBS, 5 mM hypoxan-
thine, 0.02 mM aminopterin, and 0.8 mM thymidine for
48 h.
To assess the optimal concentration of sodium selenite
for protection of EAhy926 cells from tert-BuOOH-mediated
cytotoxicity, cells were pre-incubated with a range of
selenite concentrations (0–1000 nM) for 48 h before being
washed twice with 1 ml of EBSS. For each experiment, a
concentration of tert-BuOOH was found that would kill
approximately 90% of Se-deficient cells and this was
determined from a pilot experiment that was performed
while the cells to be used for the main experiment were
being preincubated with selenite. This concentration varied
slightly between experiments ranging from approximately
200 to 300 AM tert-BuOOH. Cell damage was produced by
incubating cells with tert-BuOOH for 20 h. LDH retention
was measured as described above, all determinations being
carried out in triplicate wells.
The ability of EAhy926 cells to resist LDLox toxicity
in the presence or absence of 40 nM selenite was
determined as for tert-BUOOH above. Medium containing
either native or oxidised LDL (prepared from the same
blood donation, and diluted to a common protein value in
medium) was added to the cells at the specified concen-
trations and cells left to incubate for 20 h. LDH activity
was then measured in the medium and cell lysates as
described above, and percentage LDH retention calcu-
lated. All determinations were carried out in triplicate
wells.
3.2. Induction of TR, cyGPX, and PHGPX activities in
EAhy926 cells by selenite
EAhy926 cells were passaged into 75-cm2 flasks and
grown to 70% confluence. The cells then received medium
containing 0, 1, 10, 40, 50, 100, 200 or 1000 nM sodium
selenite (triplicate flasks for each selenite concentration,
and quadruplicate flasks for the control) for 48 h. Follow-
ing this incubation, the cells were washed twice with 10
ml EBSS, and harvested by scraping into 20 ml EBSS.
Efficiency of harvesting was determined by light micro-
scopy. The cells were then pelleted by centrifugation at
500 g for 10 min. The EBSS was aspirated, and the
pellets frozen at  70 jC until enzyme assays were carried
out. Prior to enzyme activity determinations, the cell
pellets were thawed and lysed by sonication (three pulses
of 10 s using a Soniprep 150) on ice in 0.125 M potassium
phosphate buffer (pH 7.4) containing 1 mM EDTA and
0.1% Triton X-100 (peroxide- and carbonyl-free). The
activities of the selenoenzymes were then determined as
detailed above.
3.3. Optimisation of the GTG concentration
EAhy926 cells were passaged into 75-cm2 flasks and
grown to 70% confluence. The cells then received medium
containing 0, 1, 10, or 100 AM GTG (triplicate flasks for
each GTG concentration, and quadruplicate flasks for the
control) for 48 h. Following the incubation, the cells were
washed twice with 10 ml EBSS, and harvested via scrap-
ing into 20 ml EBSS. Efficiency of harvesting was
checked by light microscopy. The cells were then pelleted
by centrifugation at 500 g for 10 min. The EBSS was
aspirated, and the pellets frozen at  70 jC until enzyme
assays were carried out. Prior to enzyme activity determi-
nations, the cell pellets were thawed, lysed and the
activities of the selenoenzymes were then determined as
described above.
3.4. tert-BuOOH and LDLox toxicity in the presence of
GTG
EAhy926 cells were passaged into 24-well plates in
either normal medium or medium containing 40 nM selen-
ite, and incubated for 48 h. After this time, the cells were
washed twice with 1 ml EBSS. Cells then received normal
unsupplemented medium, or the same medium containing
either 1 or 10 AM GTG for 48 h. When the incubation was
Table 1
The effect of sodium selenite supplementation on the activity of TR,
cyGPX, and PHGPX in EAhy926 cells [mean (U/g protein)F S.E.]
Selenite
(nM)
TR activity
(U/g protein)
cyGPX activity
(U/g protein)
PHGPX activity
(U/g protein)
0 2.0F 0.5 27.3F 1.6 5.7F 1.2
1 3.2F 0.1y 40.8F 3.9y 5.4F 0.8
10 5.3F 2.6* 115.4F 10.2z 8.8F 2.0y
50 6.1F 0.4z 138.5F 5.9z 11.1F1.1z
100 5.1F 0.3* 182.5F 26.9z 10.5F 2.5z
200 4.7F 0.3* 166.2F 29.4z 10.5F 1.1z
1000 7.4F 1.1z 153.7F 13.6z 12.6F 0.7z
Cells were cultured in 75-cm2 flasks with selenite for 48 h. All
measurements are for triplicate flasks, except the controls for which n= 4.
One unit of GPX activity was defined as 1 Amol of NADPH oxidised per
minute.
One unit of TR activity was defined as 1 Amol of DTNB reduced per
minute.
*P< 0.01 cf. control cells (ANOVA with Fisher’s test for least sig-
nificant difference).
y P < 0.05 cf. control cells (ANOVA with Fisher’s test for least sig-
nificant difference).
z P < 0.001 cf. control cells (ANOVA with Fisher’s test for least sig-
nificant difference).
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finished, the cells were again washed, and fresh medium
containing tert-BuOOH (0–250 AM) added for a 20h
incubation. LDH retention was then measured as described
above. All determinations were carried out in triplicate
wells.
The effect of 1AM GTG on modifying the susceptibility
of EAhy926 cells to LDLox was carried out in an identical
manner to that described above using an LDLox protein
concentration of 220 mg/l.
4. Results
4.1. Effect of selenite on tert-BuOOH and LDLox-induced
cell damage
Pre-incubation of EAhy926 cells with sodium selenite for
48 h showed that selenite provided optimal protection from
the cytotoxic effects of 300 AM tert-BuOOH at concen-
trations ranging from 10 to 50 nM (P < 0.0005, Fig. 1).
Selenite when added at a concentration of 1000 nM was
significantly toxic to EAhy926 cells in the absence of tert-
BuOOH (P < 0.05).
There was a concentration-dependent cytotoxicity of
LDLox (Fig. 2). Native LDL was not cytotoxic to EAhy926
cells at any of the concentrations tested. In the presence of
555 mg/l LDLox, only 19.8F 1.8% of cells survived in the
absence of selenite. In contrast, 92.7F 0.4% of cells pre-
incubated with 40 nM selenite for 48 h survived when
exposed to (555 mg/l) LDLox (P < 0.0005). This concen-
tration of 40 nM selenite was chosen as this was the lowest
concentration of selenite that gave optimal protection from
tert-BuOOH (Fig. 1).
4.2. Effect of selenite on GPX and TR activity
Incubation of EAhy926 cells with 50 nM sodium selenite
resulted in maximal expression of TR and PHGPX while
maximal expression of cyGPX was achieved at a selenite
concentration of 100 nM. Significant induction of cyGPX
(P < 0.05), and TR (P < 0.01) was first achieved with a
concentration of 1 nM selenite, and for PHGPX (P < 0.05)
with 10 nM selenite (Table 1).
4.3. Effect of GTG on GPX and TR activity
At a concentration of 1 AM GTG, 75F 7.0% of TR
activity was retained (P < 0.05 cf. control cells). There was
no significant loss of cyGPX or PHGPX activity (Table 2).
Using 10 AM GTG, 15F 10% of TR activity, 40F 4% of
cyGPX, and 65F 3% of PHGPX activity were retained
compared to control cells (P < 0.01, P < 0.05, and P < 0.005,
respectively). When GTG was added at a concentration of
100 AM, marked inhibition of all selenoenzymes was
observed such that 0.5F 0.5%, 15.0F 1.6%, and 54F 7%
of enzyme activities were retained for TR, cyGPX and
PHGPX, respectively (P < 0.0005, < 0.0005, and < 0.01 cf.
control cells).
Fig. 1. Cytoprotection of EAhy926 cells from tert-BuOOH by sodium selenite pre-incubation. Pre-incubations with sodium selenite were for 48 h, prior to
exposure to 0 AM tert-BuOOH (o) or 300 AM tert-BuOOH (5) for 20 h. Cytotoxicity was determined by LDL retention (%). All determinations are
meanF S.E. for triplicate wells. *P< 0.05; **P < 0.0005 cf. control cells (t-test for unpaired data, with Welch correction).
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4.4. Effect of GTG and/or selenite on oxidative cell damage
The LC50 for tert-BuOOH for Se-deficient cells was 175
AM. The same cells treated with either 1 or 10 AM GTG
showed an increase in susceptibility to tert-BuOOH toxicity
(LC50 = 110 and 75 AM, respectively). Cells pre-treated with
40 nM selenite were more resistant to cytotoxic damage by
tert-BuOOH in the presence of 1 AM GTG than the
corresponding cells pre-treated with 1 AM GTG alone
(LC50 195 cf. 110 AM P < 0.05), or Se-deficient cells
(Fig.3).
A similar pattern of results was found using LDLox as
the cytotoxic agent (Table 3). Cells treated with 1 AM GTG
were more susceptible to LDLox toxicity than Se-deficient
cells, while preincubation with 40 nM selenite prevented
LDL toxicity in cells treated with GTG.
Pretreatment with selenite (40 nM) or GTG (1 AM) had
no significant effect on total glutathione concentrations in
the cells (data not shown).
Table 2
The effect of gold thioglucose on the activity of TR, cyGPX, and PHGPX
in EAhy926 cells not supplemented with selenite [mean (U/g protein)F
S.E.]
GTG
(AM)
TR activity
(U/g protein)
cyGPX activity
(U/g protein)
PHGPX activity
(U/g protein)
0 1.6F 0.1 (n= 7) 39.2F 3.0 (n= 4) 5.5F 0.4 (n= 4)
1 1.2F 0.1 (n= 6)* 39.6F 2.0 (n= 3) 5.4F 0.3 (n= 3)
10 0.2F 0.1 (n= 6)z 15.6F 1.5 (n= 3)** 3.6F 0.2 (n= 3)*
100 0.01F 0.01 (n= 6)z 5.9F 0.6 (n= 3)z 3.0F 0.4 (n= 3)y
Results are activity determinations in duplicate from a minimum of trip-
licate 75-cm2 flasks incubated for 48 h.
One unit of GPX activity was defined as 1 Amol of NADPH oxidised per
minute.
One unit of TR activity was defined as 1 Amol of DTNB reduced per
minute.
*P< 0.05 cf. control cells (t-test for unpaired data, with Welch
correction).
**P< 0.005 cf. control cells (t-test for unpaired data, with Welch
correction).
y P < 0.01 cf. control cells (t-test for unpaired data, with Welch
correction).
z P < 0.0005 cf. control cells (t-test for unpaired data, with Welch
correction).
Table 3
Cytotoxicity (% LDL retention) of LDLox on EAhy926 cells pre-incubated
with GTG and selenite
Control LDLox (220 mg/l)
LDH retention (%) LDH retention (%)
No pretreatment 100F 0.1 70F 2.5*
GTG (1 AM) 99F 0.8 60F 5.1*
GTG (1 AM),
selenite (40 nM)
99F 0.4 99F 1.0
Selenite (40 nM) 98F 1.7 99F 1.6
The sodium selenite pre-incubation was for 48 h at a concentration of 40
nM. GTG pre-incubation was with 1 AM for 48 h. The cytoxicity of LDLox
was tested at 220 mg protein per liter.
Results are meanF S.E. determinations from triplicate wells.
Cells treated with GTG alone had significantly ( P < 0.05) more cell death
than cells not treated with GTG or selenite.
* Significant ( P < 0.05) differences from control cells.
Fig. 2. Cytoprotection of EAhy926 cells from LDLox by preincubation with (40 nM) selenite. Cells were pre-incubated with sodium selenite (40 nM) for 48 h.
Exposure of selenium-supplemented cells (closed symbols) or selenium-deficient cells (open symbols) to native LDL (squares) or LDLox (circles) was for 24 h.
Cytotoxicity was determined by LDH retention. Results shown are means of triplicate wellsF S.E. *P < 0.0005 cf. LDLox, cells plus Se (t-test for unpaired data).
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5. Discussion
The endothelial cell line EAhy926 [30], has been used
for a number of studies of endothelial function [8–10]. The
activities of TR and the GPXs that we have found in these
EAhy926 cells (Table 1) are similar to values we have
reported in primary cultures of human endothelial cells [17].
Furthermore, the sensitivity of EAhy926 cells to tert-
BuOOH (Fig. 1) and the concentrations of selenite that
confer optimal protection from tert-BuOOH toxicity (Fig. 1)
are also similar to previous results using HUVEC and
human coronary artery endothelial cells (HCAEC) [17].
These data taken together indicate that the EAhy926 cell
line provides an ideal and convenient model to study the
role of Se in preventing oxidative damage to human
endothelial cells.
As in HUVEC and HCAEC, oxidative damage to
EAhy926 cells by tert-BuOOH can be prevented by pre-
incubation with low nanomolar concentrations of selenite
(Fig. 1) [17]. Protection was accompanied by significantly
increased TR, cyGPX and PHGPX expression, which was
optimal with a selenite concentration of approximately 50
nM (Table 1). While tert-BuOOH is widely used as a model
agent to induce oxidative stress, in vitro, LDLox is consid-
ered to be the principal agent that damages the endothelium
and promotes atherogenesis. LDLox has also been shown to
damage EAhy926 cells in culture [8]. Supplementation of
cells with 40 nM selenite provides protection from oxidative
damage initiated by LDLox (Fig. 2). Cells preincubated
with (1 AM) GTG (a concentration that inhibited TR, but not
the GPXs), were more susceptible to toxicity from both tert-
BuOOH and LDLox than cells not exposed to this com-
pound (Fig. 3, Table 3). These data suggest that TR plays an
important role in preventing damage to human endothelial
cells from oxidised lipids. Although unlikely, these data
cannot exclude the possibility that GTG has inhibited
another, as yet, unidentified selenoenzyme with an antiox-
idant role. Cells treated with GTG at a concentration that
inhibited both TR and the GPXs (10 AM) were more
susceptible to tert-BuOOH toxicity than cells in which only
TR was inhibited. This suggests that under normal circum-
stances, both TR and the GPXs are involved in the pre-
vention of oxidative damage to human endothelial cells.
These multiple enzyme systems could act in different
cellular compartments. While glutathione is important in
preventing LDLox-induced damage [13], the doses of Se
and GTG used in our experiments produced no significant
modification to intracellular glutathione concentrations.
Gold compounds are also administered to humans for the
treatment of rheumatoid arthritis, although the mechanism
by which these compounds produce a therapeutic effect is
unknown. Reglinski et al. [39] have shown that such treat-
ment increases ‘oxidative stress’. Our data shows that GTG
increases the susceptibility of Se-deficient endothelial cells
to oxidative damage and that this damage may be prevented
by pre-treatment with selenite at doses that maximally
induce the expression of the GPXs and TR (Fig. 3, Table
3). Countries, such as the United Kingdom, have a Se intake
Fig. 3. Cytotoxicity profile of tert-BuOOH to EAhy926 cells pre-incubated with various combinations of GTG and selenite. (D) Selenite (40 nM) GTG
(1 AM), ( w ) No additions, (o) GTG (1 AM), (n) GTG (10 AM). Sodium selenite pre-incubation was for 48 h at a concentration of 40 nM. GTG pre-
incubations were for 48 h. Results are meanF S.E. determinations from triplicate wells. Significant ( P < 0.05) differences from control cells are shown by (*).
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that is insufficient to maximally induce selenoenzyme
expression [40]. It could thus be argued that in such
populations, GTG treatment may lead to damage to the
endothelium. If this were the case, such patients may benefit
from selenium supplementation prior to treatment with
GTG. However, if the efficacious effects of GTG on
rheumatoid arthritis required the production of oxidative
stress, it is possible that Se supplementation may prevent the
therapeutic action of GTG. Clinical trials would be required
to determine the potential benefits of Se supplementation
prior to GTG treatment.
Finally, our observations support the view that a low Se
status would promote endothelial injury and atherosclerosis
initiated by LDLox in humans [41–43]. There are no reports
to our knowledge that show in vivo how the Se content of
the endothelium responds to Se supplementation. However,
our results suggest that selenium supplementation at doses
which optimise the expression of the TR and the GPXs may
have significant beneficial effects when applied to popula-
tions that have an Se intake below that currently recom-
mended. Properly conducted controlled trials of selenium
supplementation are urgently required.
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